Clene Inc.
$ 5.28
-1.12%
07 Aug - close price
- Market Cap 67,469,000 USD
- Current Price $ 5.28
- High / Low $ 5.57 / 5.27
- Stock P/E N/A
- Book Value -1.60
- EPS -3.23
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.56 %
- ROE -17.38 %
- 52 Week High 13.50
- 52 Week Low 3.50
About
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.
Analyst Target Price
$32.20
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.37 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CLNN
2026-08-07 18:40:55
Clene Inc. (CLNN) has an earnings forecast score of 8.00, ranking 171 out of 387 in its industry, with an average analyst price target of $30.00. Analysts largely recommend a "Buy" for the stock, anticipating a significant upside. The company's next expected revenue is $73.50K, and the next quarter's EPS is projected to be -$0.37.
2026-08-06 17:39:42
Clene Inc. insider Chidozie Ugwumba has reported a disposal of beneficial ownership of warrants for 799,358 common shares, held indirectly through SymBiosis II LLC, due to a restructuring. Management of the fund's portfolio transferred to an unaffiliated third party, meaning Ugwumba no longer has voting or investment power over these securities and is no longer considered a ten percent owner subject to Section 16 reporting. No warrants were exercised, sold, or transferred in this internal shift.
2026-08-04 14:11:24
Empery Asset Management, LP and Ryan M. Lane have disclosed a 7.17% beneficial ownership stake in Clene Inc. (CLNN) through a Schedule 13G SEC filing. This stake represents 916,532 shares of common stock, based on 12,778,307 shares outstanding as of May 11, 2026. The filing indicates shared voting and dispositive power over these shares, with each reporting person disclaiming beneficial ownership of shares held by the others.
2026-08-03 00:47:18
This article provides an earnings forecast for Clene Inc. (CLNN), highlighting its current earnings forecast score of 8.00 within the Biotechnology & Medical Research industry. Analysts project an average price target of $30.00 for CLNN, with most recommending a "Buy" trend. The company's expected revenue for the next quarter is $73.50K, and the expected EPS is -$0.37.
2026-07-31 10:11:29
This article provides a comprehensive stock analysis of Clene Inc. (CLNN) based on TradingKey's Stock Score. It highlights the company's relatively stable fundamentals, high growth potential, and fair valuation within the Biotechnology & Medical Research industry. Despite recent weak market performance, CLNN shows strong fundamentals, with analysts rating it as "Buy" and expecting a downward trend in the medium term.
2026-07-30 00:39:28
The article provides a detailed financial overview of Clene Inc. (CLNN), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, revenue, net profit, and various margins over several quarters and fiscal years. Additionally, it addresses frequently asked questions regarding the company's total revenue, assets, liabilities, equity, and profitability figures from its FY2025 earnings report.
